Economic Evaluation of Dupilumab versus Endoscopic Sinus Surgery for the Treatment of Chronic Rhinosinusitis with Nasal Polyps.
Arjun K ParasherMatt GliksmanDaniel SegarraTheodore C LinLuke RudmikTroy QuastPublished in: International forum of allergy & rhinology (2021)
While dupilumab and ESS may demonstrate similar clinical effectiveness, ESS remains the most cost-effective treatment option and should remain standard of care for CRSwNP patients refractory to medical therapy. This article is protected by copyright. All rights reserved.
Keyphrases
- chronic rhinosinusitis
- healthcare
- end stage renal disease
- minimally invasive
- chronic kidney disease
- palliative care
- systematic review
- ejection fraction
- newly diagnosed
- stem cells
- prognostic factors
- replacement therapy
- bone marrow
- ultrasound guided
- quality improvement
- acute coronary syndrome
- peritoneal dialysis
- percutaneous coronary intervention
- surgical site infection
- chemotherapy induced